Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

dc.contributor.author	Bilir, A.
dc.contributor.author	Erguven, M.
dc.contributor.author	Ermis, E.
dc.contributor.author	Sencan, M.
dc.contributor.author	Yazihan, N.
dc.date.accessioned	2021-12-21T08:41:59Z
dc.date.available	2021-12-21T08:41:59Z
dc.date.issued	2011
dc.identifier.issn	20050380
dc.identifier.uri	https://doi.org/10.3802/jgo.2011.22.4.225
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1565
dc.description.abstract	Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies. Methods: Im
dc.language.iso	English
dc.rights	All Open Access, Green
dc.title	Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
dc.type	Article
dc.relation.journal	Journal of Gynecologic Oncology
dc.identifier.issue	4
dc.identifier.startpage	225
dc.identifier.endpage	232
dc.identifier.volume	22
dc.identifier.doi	10.3802/jgo.2011.22.4.225
dc.relation.issue	4
dc.relation.volume	22